

# AMA/CME Test 217

## Mifepristone

(Test valid through December 31, 2002)

This activity has been planned and produced in accordance with ACCME Essentials.  
The estimated time to complete this activity is 1 hour.

**Instructions:** Read the article beginning on page 45 and select the best answer for each of the following questions.  
Test form and mailing instructions are on the next page.

1. Mifepristone (RU 486) was first studied as an abortifacient in humans in:
  - a. Sweden nearly 30 years ago.
  - b. France nearly 20 years ago.
  - c. the United States in the early 1980s.
  - d. China in the late 1970s.
2. What proportion of US women live in counties that do not have surgical abortion providers?
  - a. one-fourth
  - b. one-third
  - c. one-half
  - d. two-thirds
3. Fill in the blank: Mifepristone serve as an abortifacient because of its affinity for the \_\_\_\_\_ receptor.
  - a. progesterone
  - b. mineralocorticoid
  - c. estrogen
  - d. androgen
4. Fill in the blank: For medical abortion in the United States, mifepristone must be given less than \_\_\_ days after day 1 of the last menstrual period.
  - a. 63
  - b. 56
  - c. 49
  - d. 42
5. Which is *not* a contraindication to mifepristone use?
  - a. suspected ectopic pregnancy
  - b. intrauterine device in place
  - c. concurrent, long-term corticosteroid use
  - d. prior long-term oral contraceptive use
6. Which is *not* a necessary qualification for prescribing mifepristone?
  - a. ability to estimate fetal age based on ultrasonography
  - b. ability to diagnose ectopic pregnancy
  - c. certification by state licensing board
  - d. provision of full explanation of medical abortion procedure to patient
7. What is the success rate of the mifepristone/misoprostol regimen in the United States?
  - a. 92%
  - b. 88%
  - c. 85%
  - d. 100%
8. Fill in the blank: A mifepristone dose of \_\_\_\_\_, given within 72 hours after unprotected intercourse, is effective as emergency postcoital contraception.
  - a. 200 mg
  - b. 400 mg
  - c. 600 mg
  - d. 1200 mg
9. Potential nonobstetric indications for mifepristone include all of the following, *except*:
  - a. endometriosis treatment.
  - b. recurrent breast cancer prophylaxis.
  - c. Cushing's syndrome treatment
  - d. uterine fibroid treatment.
10. Which of the following medications may *increase* serum mifepristone levels?
  - a. dexamethasone
  - b. phenytoin
  - c. St John's wort
  - d. ketoconazole

# THE FEMALE PATIENT® / Test 217

**Mifepristone** (Test valid through December 31, 2002. No credit will be given after that date.)

Record your answers here by circling the appropriate letter:

1. a b c d
2. a b c d
3. a b c d
4. a b c d
5. a b c d
6. a b c d
7. a b c d
8. a b c d
9. a b c d
10. a b c d

Name

*(Please print)*

*Last*

*First*

*Initial*

Specialty

Address

City

State/ZIP

Phone #

For you to obtain credit, 70% or more of your answers must be correct. To cover costs of processing, please enclose a check for \$10, which is tax-deductible, payable to the Division of Continuing Medical Education (TFP), and mail with this answer sheet to:

**TFP-CME BOX #2**  
QUADRANT HEALTHCOM INC.  
26 Main St.  
Chatham, NJ 07928-2402

Participants will receive certification for their records in approximately 10 to 12 weeks.

## Course Evaluation

Albert Einstein College of Medicine would like to have your opinion. Your evaluation will help us to plan future CME tests for THE FEMALE PATIENT®. We urge you to complete this questionnaire and mail it back to us with your completed test. Thank you for your cooperation.

1. How do you rate the information in this article?

Superior       Satisfactory       Unsatisfactory

2. Will the materials presented influence the way you treat your patients?       Yes       No

3. Did this activity meet its objectives?

Yes       No

4. What recommendations do you have to improve this activity?

---

---

---

5. Were any portions of this activity unsatisfactory or inappropriate? If so, which ones?

---

---

6. Do you find the information presented in this activity to be fair, objective, and balanced?       Yes       No

7. What subjects would you include in future activities?

---

---

8. In your opinion, was the author biased in her discussion of any commercial product or service?

Yes       No

Comments

---

---